Zydus Cadila’s formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) signifying the successful closure of the audit. The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations. Post the audit, the plant has received several product approvals, including the final approval to market Mesalamine Delayed- Release Tablets USP, 1.2 g in the US.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
